Petros Pharmaceuticals Inc. (PTPI) News
Filter PTPI News Items
PTPI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PTPI News From Around the Web
Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in discussions with third-party technology partnersNEW YORK, ... |
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAImportant step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding ... |
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelCompany well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication ... |
Petros Pharmaceuticals to Present at the LD Micro Main Event XVINEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief ... |
Petros Pharmaceuticals Provides Letter to ShareholdersPetros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders: |
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference/ Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! |
Petros Pharmaceuticals Announces Capital Raise of $15 MillionPetros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status. |